CASE PRESENTATION
=================

A 47-year-old man was admitted to hospital with worsening malaise, fatigue, drenching night sweats, anorexia and a 15 kg weight loss. Four months previously, he developed dyspnea, orthopnea, exertional chest heaviness and a single episode of hemoptysis, for which he had been empirically treated with two 10-day courses of oral antibiotics (cefuroxime, then clarithromycin). Transient swelling, erythema and tenderness over his shins ensued, followed by numbness of his fingers and the left side of his body. These neurological symptoms had improved, but not resolved, at presentation. A dental procedure (unknown) had been performed 12 months before symptom onset.

On examination, he appeared unwell. His temperature was 36.8°C, heart rate 80 beats/min, blood pressure 95/50 mmHg, respiratory rate 18 breaths/min and oxygen saturation 99% on 3 L nasal prongs. Cardiovascular examination revealed a soft S2, an S3, a grade II/VI aortic systolic ejection murmur and a grade III/VI diastolic decrescendo murmur at the left lower sternal border, without signs of congestive heart failure. Fundoscopic examination revealed changes consistent with hypertension, but did not demonstrate retinal hemorrhages or Roth's spots. Oral hygiene was unremarkable. There was a tender area of induration on the palm of his left hand and the dorsum of his left foot ([Figure 1A](#f1-idmm-26-41){ref-type="fig"}), but no erythema nodosum. The spleen was palpable.

Abnormal laboratory investigations included a white blood cell count of 14.1×10^9^/L (normal values 4×10^9^/L to 11×10^9^/L), neutrophils 11×10^9^/L (normal values 2×10^9^/L to 8×10^9^/L), a normocytic, normochromic anemia with a hemoglobin level of 117 g/L (normal level 137 g/L to 180 g/L) and elevated inflammatory markers (C-reactive protein level 64 mg/L \[normal level 0 mg/L to 8 mg/L\] and erythrocyte sedimentation rate 28 mm (normal value 0 mm to 10 mm). Three temporally distinct sets of blood cultures were obtained, and empirical therapy with intravenous vancomycin and ceftriaxone was initiated. Magnetic resonance angiography of the brain and a transesophageal echocardiogram were obtained.

DIAGNOSIS
=========

Transesophageal echocardiogram demonstrated a 1.7 cm vegetation on a previously unrecognized bicuspid aortic valve, with severe aortic insufficiency ([Figure 1B](#f1-idmm-26-41){ref-type="fig"}). Magnetic resonance angiography of the brain revealed a focus of restricted diffusion in the corpus callosum, concerning for an infarct. By 48 h, all blood cultures yielded a Gram-negative bacillus (oxidase positive, catalase negative and urease negative) identified as *Cardiobacterium hominis* ([Figure 1C](#f1-idmm-26-41){ref-type="fig"}). The identification was confirmed by matrix-assisted laser desorption ionization time-of-flight (Vitek MS) and the Vitek NH identification card (bioMérieux Canada Inc, Canada). At the time of aortic valve replacement, both native aortic leaflets were markedly thickened and a perivalvular abscess was observed at the aortic valve root, which subsequently grew *C hominis*.

Initial Etest (bioMérieux Canada Inc) results, using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood (MHB), demonstrated resistance to ceftriaxone and cefotaxime ([Figure 1D](#f1-idmm-26-41){ref-type="fig"}). The nitrocefin-based test (Nitrocefin SR112, Oxoid Microbiology Products, USA) for beta-lactamase production was negative. Subsequently, broth microdilution (BMD) in cation-adjusted Mueller-Hinton broth supplemented with 5% lysed horse blood (CAMHB-LHB) as well as Etest susceptibilities using *Brucella* blood agar ([@b1-idmm-26-41]) demonstrated susceptibility to all agents tested ([Table 1](#t1-idmm-26-41){ref-type="table"}).

DISCUSSION
==========

Endovascular infection with *C hominis*, a member of the HACEK group of microorganisms (*Haemophilus* species, *Actinobacillus actinomycetemcomitans*, *Cardiobacterium hominis*, *Eikenella corrodens* and *Kingella* species), is usually insidious in onset, with a prolonged subacute course characterized by leukocytosis, anemia, splenomegaly, embolic phenomena, congestive heart failure and weight loss ([@b2-idmm-26-41]). Dental work (as well as routine oral hygiene/quality of dentition) and bicuspid aortic valve are both well-documented risk factors for developing infective endocarditis due to HACEK microorganisms ([@b2-idmm-26-41]). Our patient typified these characteristics.

Although *C hominis* is of relatively low virulence, endovascular infection complicates 95% of all cases of bacteremia, with the aortic valve being most commonly affected ([@b3-idmm-26-41],[@b4-idmm-26-41]). Almost one-half of patients require valve replacement. Peripheral and central nervous system emboli occur frequently in *C hominis* endocarditis, noted in 51% and 21% of cases, respectively, especially when the aortic valve is involved ([@b3-idmm-26-41],[@b5-idmm-26-41],[@b6-idmm-26-41]). Extravascular infection is unusual ([@b7-idmm-26-41]). Prognosis is generally favourable, with a 93% cure rate for both native and prosthetic valve infection ([@b3-idmm-26-41]). A third-generation cephalosporin is the drug of choice for infection with HACEK organisms ([@b8-idmm-26-41]).

In our patient, initial minimum inhibitory concentration determinations using Etest methodology on MHB agar demonstrated resistance to third-generation cephalosporins (nitrocephin negative). This complicated early management of the patient because it appeared to preclude the use of first-line therapy for *C hominis* endocarditis. Repeat testing with Clinical and Laboratory Standards Institute (CLSI)-approved reference methods ([@b1-idmm-26-41]) demonstrated susceptibility to third-generation cephalosporins. We were unable to reproduce this 'major' error with other recent *C hominis* isolates (n=5) in our laboratory (data not shown).

Penicillin resistance due to beta-lactamase production has been documented in *C hominis* ([@b9-idmm-26-41],[@b10-idmm-26-41]), but cephalosporin resistance has only been described in a single case report ([@b9-idmm-26-41]) based on disc diffusion testing. Guidelines for susceptibility testing of fastidious organisms, including the HACEK group, are relatively new ([@b1-idmm-26-41]). For *Cardiobacterium* species, the recommended testing method is BMD in CAMBH-LHB (as for pneumococcus and other fastidious organisms). Although not endorsed by CLSI, many laboratories use Etest or other gradient strip methodologies for ease of use and accessibility. In the present case, use of a non-CLSI-approved antibiotic gradient strip susceptibility testing methodology resulted in a 'major' error. The risk of a 'very major' error cannot be ascertained.

The likely cause of the 'major' error was the use of an antibiotic gradient susceptibility testing method with media (MHB) not adequately validated in microbiological studies. MHB agar has previously been used in agar dilution and Etest methodologies for other HACEK-group organisms ([@b11-idmm-26-41]--[@b13-idmm-26-41]). The Etest application guide recommends using either *Brucella* blood agar or Mueller-Hinton agar with 1% hemoglobin and 1% IsoVitalex (BD, USA) for HACEK organisms ([@b14-idmm-26-41]); however, the cited literature provides no data on the use of Mueller-Hinton agar for susceptibility testing of *C hominis*. Penicillinase or cephalosporinase production appeared to be unlikely based on a negative nitrocefin test. A subpopulation of *C hominis* with isolated resistance to cephalosporins due to specific penicillin-binding protein mutations (as has been described in *Streptococcus pneumoniae* \[[@b15-idmm-26-41]\]) was also considered to be unlikely given that the intermediate zones did not grow when subcultured to another agar plate and the repeated susceptibility testing using BMD did not show any evidence of resistance.

Returning to the case, the patient received six weeks of intravenous ceftriaxone following his aortic valve replacement, rather than a standard four-week course ([@b8-idmm-26-41]), because of his septic cerebral embolus. Repeat echocardiography demonstrated complete resolution of his perivalvular abscess and a properly functioning prosthetic aortic valve. His neurological symptoms continued to improve, although he still had residual left-sided numbness at three-month follow-up. This case highlights both the typical clinical presentation of endovascular infection with *C hominis* and the potential issues that may arise when performing susceptibility testing for fastidious organisms in the clinical microbiology laboratory.

The authors thank Dr Johann Pitout for his assistance in this case.

![**A** *Focal area of induration on dorsum of left foot.* **B** *Transesophageal echocardiogram (parasternal short axis view) demonstrating a bicuspid aortic valve with a large vegetation.* **C** *Gram stain of blood culture demonstrating Gram-negative bacilli consistent with* Cardiobacterium hominis. **D** *Etest (bioMérieux Canada, Inc) results for ceftriaxone with a double zone of inhibition at a minimum inhibitory concentration of 0.023 μg/mL and 16 μg/mL. Bacteria within the intermediate zone of inhibition could not be cultured*](idmm-26-41-1){#f1-idmm-26-41}

###### 

Summary of minimum inhibitory concentrations for *Cardiobacterium hominis* isolates

  **Antibiotic**                  **Minimum inhibitory concentration (μg/mL) by method and media**   **CLSI interpretive criteria (μg/mL)**                                      
  ------------------------------- ------------------------------------------------------------------ --------------------------------------------------- ------------ ---------- -------
  Penicillin                      0.5                                                                ≤0.016                                              ≤0.06        ≤1         ≥4
  Ampicillin                      0.094                                                              0.023                                               ≤0.06        ≤1         ≥4
  Amoxicillin-clavulanate         0.5^[†](#tfn2-idmm-26-41){ref-type="table-fn"}^                    0.023^[†](#tfn2-idmm-26-41){ref-type="table-fn"}^   ≤0.5/0.25    ≤4/2       ≥8/4
  Imipenem                        0.032                                                              0.006                                               No data      ≤0.5       ≥2
  Meropenem                       0.006                                                              ≤0.002                                              ≤0.06        ≤0.5       ≥2
  Ceftriaxone                     16                                                                 0.016                                               ≤0.25        ≤2         --
  Cefotaxime                      32                                                                 0.094                                               ≤0.25        ≤2         --
  Levofloxacin                    0.012                                                              0.008                                               ≤0.25        ≤2         ≥8
  Trimethoprim-sulfamethoxazole   0.094^[‡](#tfn3-idmm-26-41){ref-type="table-fn"}^                  0.016^[†](#tfn2-idmm-26-41){ref-type="table-fn"}^   ≤0.25/4.75   ≤0.5/9.5   ≥4/76

Clinical Laboratory Standards Institute methodology (CLSI);

Amoxicillin concentration;

*Trimethoprim concentration. BMD Broth microdilution; BBA* Brucella *blood agar; CAMHB-LHB Cation-adjusted Mueller-Hinton broth with 5% lysed horse blood; MHB Mueller-Hinton agar with 5% sheep blood*
